Home Care Equivalent To Hospital Care For Some Patients With Cystic Fibrosis
Patients with cystic fibrosis (CF) recover from exacerbations equally well if they are treated at home or in a hospital, according to researchers from Johns Hopkins University. Furthermore, longer treatment with antibiotics does not appear to offer any additional benefit over shorter courses...

Teens Urge Congress To Help Their Siblings With Cystic Fibrosis
Teens from across the United States whose siblings have cystic fibrosis will press their elected officials in Washington, D.C., June 24, to fund drug research and increase access to clinical trials for those with rare diseases. Their goal is to speed the development of new drugs for people who need them most...

ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation)...

Detection Of MRSA In Cystic Fibrosis Patients Associated With Shorter Survival
Patients with cystic fibrosis (CF) who have Methicillin-resistant Staphylococcus aureus (MRSA) detected in their respiratory tract have worse survival compared to CF patients without MRSA, according to a study in the June 16 issue of JAMA. The most common cause of death in CF is respiratory failure secondary to pulmonary infection...

Eurand Announces Data On Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency From Unapproved PEPs To FDA-Approved ZENPEP(R)
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V...

Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
Centocor Ortho Biotech Inc. announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases...

'Orphan Drug' Research Offers Hope
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S...

Insight Into The Future Of Cystic Fibrosis Offered By Older Patients
An emerging population of middle-aged cystic fibrosis patients contains significantly more females and includes a large proportion of patients who lived for decades without a diagnosis or specialized care, according to research published by researchers at National Jewish Health...

NIH Director Francis Collins And CF Foundation To Brief U.S. Senate On Advancing Disease Research
National Institutes of Health (NIH) Director Francis S. Collins, M.D., Ph.D., will lead a briefing on Capitol Hill Thursday, May 20, to discuss how funding for medical research at the NIH can be used more quickly to create new therapies for patients and save lives...

Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results Of Aeroquin(TM) (MP-376) Treatment In Cystic Fibrosis Patients
Mpex Pharmaceuticals, Inc. announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans...

Gregory Downey, MD, Honored For Scientific Accomplishments
Gregory Downey, MD, received the 2010 Recognition Award for Scientific Accomplishments at the American Thoracic Society's (ATS) International Conference on Monday, May 17. Dr. Downey, Executive Vice President of Academic Affairs and Professor of Medicine, Pediatrics and Immunology at National Jewish Health, has over 190 publications to his credit...

MP-376 Safe And Effective For Treatment Of P. Aeruginosa In CF Patients
New possible treatment to treat P. aeruginosa in cystic fibrosis (CF) patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans. Approximately 80 percent of CF patients develop chronic P. aeruginosa lung infection, and antibiotic resistance is an increasing problem...

Aradigm Receives FDA Clearance For Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Pediatric Patients With Cystic Fibrosis
Aradigm Corporation (OTCBB:ARDM) (the "Company") announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application...

Use Of Antibiotic By Children With Cystic Fibrosis Does Not Result In Improved Lung Function
Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA. "A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis (CF)...

Cystic Fibrosis Foundation Launches National Cycling Series To Benefit Critical Research And Care
Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP® CF Cycle for Life begins in San Francisco on June 26. The event's title sponsor is Eurand N.V...